Compare CLNE & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLNE | LYEL |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | 161 |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.4M | 556.1M |
| IPO Year | 2006 | 2021 |
| Metric | CLNE | LYEL |
|---|---|---|
| Price | $2.29 | $23.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $3.32 | ★ $30.60 |
| AVG Volume (30 Days) | ★ 1.5M | 74.3K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $341,599,000.00 | $36,000.00 |
| Revenue This Year | $1.13 | N/A |
| Revenue Next Year | $22.65 | $16,285.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.32 | $0.39 |
| 52 Week High | $3.11 | $45.00 |
| Indicator | CLNE | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.88 | 55.08 |
| Support Level | $2.07 | $21.27 |
| Resistance Level | $2.30 | $27.30 |
| Average True Range (ATR) | 0.12 | 1.71 |
| MACD | -0.02 | 0.43 |
| Stochastic Oscillator | 15.00 | 74.68 |
Clean Energy Fuels Corp is a natural gas marketer and retailer operating in the United States and Canada. The company supplies compressed natural gas and liquefied natural gas for the United States (U.S.) and Canadian transportation markets. The majority of revenue is generated within the U.S. and mostly consists of compressed natural gas. The firm operates by purchasing natural gas from local utilities; compressing, cooling, or liquefying it at company-owned plants; and selling natural gas products through company-owned or customer-owned fueling stations. It also builds, operates, and maintains natural gas fueling stations for customers.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.